The first Rubius Therapeutics trade was made in Q2 2019.
Since then Ken Griffin bought shares six more times and sold shares on seven occasions. The investor completely sold their stake between Q3 2022 and Q1 2023.
Avg closing price
Price range
Sold -132 Thousand shares
Q1 2023
Avg closing price
$0.15
Price range
$0.02
-
$0.34
Sold 6.7% shares (-9.46 Thousand shares)
Q4 2022
Avg closing price
$0.27
Price range
$0.14
-
$0.45
Sold 59.8% shares (-211 Thousand shares)
Q3 2022
Avg closing price
$0.75
Price range
$0.43
-
$1.29
Increased shares by 22.3% (+64.3 Thousand shares)
Q2 2022
Avg closing price
$1.68
Price range
$0.79
-
$5.98
Increased shares by 374.2% (+228 Thousand shares)
Q1 2022
Avg closing price
$6.35
Price range
$4.25
-
$10.40
Increased shares by 219.4% (+41.8 Thousand shares)
Q4 2021
Avg closing price
$13.87
Price range
$9.68
-
$17.74
New holding (+19 Thousand shares)
Q3 2021
Avg closing price
$21.75
Price range
$17.60
-
$25.91
Sold -83.3 Thousand shares
Q1 2021
Avg closing price
$14.61
Price range
$8.02
-
$32.00
Increased shares by 147.1% (+49.6 Thousand shares)
Q3 2020
Avg closing price
$5.30
Price range
$4.65
-
$6.25
Sold 76.0% shares (-107 Thousand shares)
Q2 2020
Avg closing price
$5.90
Price range
$4.01
-
$6.88
Sold 27.2% shares (-52.5 Thousand shares)
Q1 2020
Avg closing price
$7.43
Price range
$3.74
-
$9.84
Sold 27.6% shares (-73.6 Thousand shares)
Q4 2019
Avg closing price
$9.67
Price range
$7.23
-
$14.12
Increased shares by 24.0% (+51.5 Thousand shares)
Q3 2019